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Antibodies Targeting Cell Surface Molecules Signaling Lymphocyte Activating Molecule-F7
Signaling lymphocyte activating molecule-F7 (SLAMF7) (CS1, CD2 subset Similarly, MOR202 (MorphoSysAG), a fully human anti-CD38 IgG1 MoAb produced by a human combinatorial antibody library (HuCAL) platform, also efficiently triggers ADCC against CD38+ myeloma cell lines and patient myeloma cells in vitro as well as in vivo in a xenograft mouse model. 25 Hence, anti-CD38 MoAbs appear to be a promising option as monotherapy as well as the Len/daratumumab combination. However, one practical problem in applying anti-CD38 therapy is the wide expression on lymphoid, myeloid, and epithelial cells, especially following cell activation.
Syndecan-1
Syndecan-1 (CD138) is a heparan sulfate proteoglycan that serves as a receptor for epidermal growth factor (EGF) ligands. It is frequently present on normal and myeloma plasma cells and is involved in cell adhesion, maturation, and proliferation. When present at high levels in the serum, CD138 is an independent indicator of poor prognosis. 26, 27 Also, almost all myeloma cells, even after exposure to multiple therapies, express the antigen, making it a useful target at any stage of the disease.
Three new murine/human chimeric anti-CD138 antibody-maytansinoid conjugates; nBT062-SMCC-DM1, nBT062-SPDB-DM4, and nBT062-SPP-DM1
were found to have antitumor efficacy against myeloma cell lines and primary tumor cells from MM patients by inducing G2-M cell cycle arrest, followed by apoptosis associated with cleavage of caspase-3, caspase-8, caspase-9, and poly (ADP-ribose) polymerase. They vary in their linkage between the maytansinoid moiety and MoAb. Nonconjugated nBT062 completely block cytotoxicity induced by nBT062-maytansinoid conjugate, confirming that By contrast, there have been other studies that demonstrated that the CD20+ phenotype is associated with t(11, 14) (q13; q32) cytogenetic abnormality and with shorter survival. 34 Also, circulating clonotypic cells with properties similar to normal memory B cells have been found
to have clonogenic potential in MM. 35 Hence, it may be too soon to consider it ineffective and clinical trials using rituximab in MM deserve further investigation.
Cluster of Differentiation 40
CD40 is a transmembrane protein belonging to the tumor necrosis factor (TNF)-α superfamily, which is expressed in high levels on the surface of myeloma cell lines and primary myeloma cells. 36 The binding of CD40 to its natural ligand leads to myeloma cell proliferation and migration via the phosphatidylinositol-3 kinase (PI3K)-Akt-nuclear factor kappa-lightchain-enhancer of activated B cells (NF-kB) signaling. 37 CD40 is also expressed by BMSCs and upon activation it triggers the secretion of IL-6 and vascular endothelial growth factor (VEGF) pathway. 38, 39 Two MoAbs targeting CD40 activation in myeloma cells, lucatumumab (also known as HCD122) and dacetuzumab (also known as SGN-40), have been investigated. Lucatumumab is a fully human, recombinant IgG1 type anti-
CD40. An open-label, multicenter, phase I study found that single-agent lucatumumab was well tolerated up to a dose of 4.5 mg/kg. It induced SD in 43 % and PR in 7 % of RRMM patients. 40 Dacetuzumab is a humanized anti-CD40 MoAb. In a phase I study, it was found to be well tolerated, but did not produce any objective responses. 41 However, preliminary in vitro data suggested that combining dacetuzumab with Len is synergistic. 42 Hence, a phase I study using this combination in RRMM patients was conducted. The regimen was generally well tolerated with fatigue, neutropenia, and thrombocytopenia as the most common adverse events. It showed an ORR of 61 % in Len-naïve patients and 28 % in patients previously treated with Len. demonstrated an overall favorable safety profile. Three patients showed mixed response, eight patients showed SD, and two patients remained on treatment for 42 weeks. 46 In a phase I study of lorvotuzumab mertansine in combination with Len/Dex in patients with CD56-positive RRMM, the responses were modest. The most common adverse event was peripheral neuropathy, which occurred more frequently at higher doses (55 % at 75 mg/m 2 and 100 % at 90 and 112 mg/m 2 ) and after three cycles. 47 Owing to the synergistic activity with Len and Btz, 48 phase I studies utilizing this combination are presently ongoing.
Cluster of Differentiation 74
CD74 expression has been demonstrated in more than 80 % of MM cases. 49 Milatuzumab (also known as IMMU-110) is an immunoconjugate composed of doxorubicin conjugated to an anti-CD74 MoAb, LL1. A phase I multicentric study evaluated milatuzumab in patients with RRMM.
Initially, infusion reactions were reported as the dose-limiting toxicity. After increasing prophylactic medications and slowing administration they were only of grade 1 or 2 intensity. However, there were severe adverse effects including bacterial meningitis, fever, unexplained drop in hemoglobin, cord compression, confusion, hypercalcemia, and thrombocytopenia. 
Others Potential Targets
Other potential targets are CD48, CD70, CD229, GM-2 ganglioside, programmed cell death protein-1 (PD-1), beta 2 microglobulin, insulin-like growth factor 1 receptor (IGF-1), human leukocyte antigen-DR (HLA-DR),
and TRAIL signaling pathways, the antibodies against which are presently studied in various preclinical and clinical trials.
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Antibodies Targeting Cytokines in Tumor Microenvironment
The BM microenvironment encompasses a wide spectrum of cell types with the myeloma disease burden. [64] [65] [66] The inhibition of the wingless (Wnt) pathway suppresses osteoblasts, whereas the amplification of the receptor activator of nuclear factor-kappa B (RANK) pathway and the action of macrophage inflammatory protein-1-alpha (MIP1α) activates osteoclasts. 64 The induction of proangiogenic molecules (e.g., VEGF) enhances the microvascular density of BM and accounts for the abnormal structure of myeloma tumor vessels. 65 Hence, these cytokines and the downstream pathways appear to be an interesting target for immunotherapy.
Interleukin-6
IL-6 is a key cytokine predominantly produced by BMSCs. It mediates myeloma cell growth and prevents apoptotic cell death via at least three 
Vascular Endothelial Growth Factor
In addition to its angiogenic effects, VEGF also functions as a growth factor for myeloma cells, stimulates IL-6 production in BMSCs, triggers myeloma cell migration, and inhibits maturation of dendritic cells. Elevated levels of VEGF have been associated with poor survival in MM patients.
73
A phase II study of the bevacizumab with Len and pulse Dex in RRMM
showed an encouraging ORR of 70 % in the 27 evaluable patients.
However, these outcomes were was not statistically superior to the 60 % ORR achieved in previously treated MM patients who received Len and high-dose Dex. 74 Also, the addition of bevacizumab to Btz was well tolerated in unselected patients with pretreated MM. But the combination did not result in significant improvements in efficacy outcomes. BHQ880 is a fully human anti-DKK1 MoAb. Although BHQ880 had no direct effect on myeloma cell growth, BHQ880 increased osteoblast differentiation, neutralized the negative effect of myeloma cells on osteoblastogenesis,
and reduced IL-6 secretion. 86 Furthermore, in a SCID-hu murine model of human MM, BHQ880 treatment led to a significant increase in osteoblast number, serum human osteocalcin level, and trabecular bone. 87 A phase IB multicentric, dose-determination study of BHQ880 in combination with anti-myeloma therapy and ZA in patients with RRMM and prior SRE was conducted. It revealed that the combination was well tolerated with a general trend towards increased bone mineral density. 88 Activin A Activin A is a transforming growth factor-beta (TGF-β) superfamily member most commonly associated with embryogenesis and gonadal hormone signaling. 89 In addition, activin A is also involved in bone remodeling by stimulating osteoclasts growth and inhibiting osteoblasts differentiation. At present, it remains to be defined how MoAb therapy can most productively be incorporated into the current therapeutic paradigms that will help to achieve longer disease control and significant survival gains in patients with MM either as short-term induction therapy, frontline treatment in transplant ineligible patients, or long-term maintenance therapy post-ASCT/induction cytotoxic therapy.
Future experiments may be directed at inclusion of MoAbs in standard therapy against MM, evaluation of targets, the antibodies against which will hinder the progression from smoldering to symptomatic MM, and of biomarkers to identify patient subsets that are most likely or unlikely to respond to specific MoAbs. n
